Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire

Janice N. Cormier, Merrick I. Ross, Jeffrey E. Gershenwald, Jeffrey E. Lee, Paul F. Mansfield, Luis H. Camacho, Kevin Kim, Kimberly Webster, David Cella, J. Lynn Palmer

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

BACKGROUND. The authors previously developed a melanoma-specific module for the Functional Assessment of Cancer Therapy (FACT-Melanoma), a tool for the assessment of quality of life (QOL) in patients with melanoma. The reliability and validity of the FACT-Melanoma was examined in this study. METHODS. Patients with melanoma (N = 273; stages I-IV) completed a battery of questionnaires at the time of enrollment. The validity of the instrument was examined by comparing FACT-Melanoma scores with performance status, disease stage, treatment status, and other scales, including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Melanoma Module, the Profile of Mood States, and the Marlowe-Crowne Social Desirability Scale. Patients were assessed after 1 week to assess test-retest reliability and at 3 months to determine the sensitivity of the instrument to change in performance status. RESULTS. The internal consistency and test-retest reliability (r) of the melanoma subscale (Cronbach α = .85; r = .81) and the total FACT-Melanoma (α = .95; r = .90) were excellent. Overall, the scales were correlated with other measures, as anticipated. Total FACT-Melanoma scores, along with scores for physical well-being, emotional well-being, functional well-being, and melanoma-specific scales, were lower for patients with advanced (stage III/IV) melanoma, poor performance status, and patients who were receiving active treatment. The FACT-Melanoma total score and the score for physical well-being were sensitive to changes in performance status (P = .0012 and P = .004, respectively). CONCLUSIONS. The results of the current study indicated that the FACT-Melanoma questionnaire is a reliable and valid instrument for patients with melanoma that can be used for the assessment of QOL in clinical trials.

Original languageEnglish (US)
Pages (from-to)2249-2257
Number of pages9
JournalCancer
Volume112
Issue number10
DOIs
StatePublished - May 15 2008

Fingerprint

Reproducibility of Results
Melanoma
Neoplasms
Therapeutics
Quality of Life
Surveys and Questionnaires
Social Desirability

Keywords

  • Melanoma
  • Patient-reported outcomes
  • Quality of life
  • Test-retest reliability

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cormier, J. N., Ross, M. I., Gershenwald, J. E., Lee, J. E., Mansfield, P. F., Camacho, L. H., ... Palmer, J. L. (2008). Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire. Cancer, 112(10), 2249-2257. https://doi.org/10.1002/cncr.23424
Cormier, Janice N. ; Ross, Merrick I. ; Gershenwald, Jeffrey E. ; Lee, Jeffrey E. ; Mansfield, Paul F. ; Camacho, Luis H. ; Kim, Kevin ; Webster, Kimberly ; Cella, David ; Palmer, J. Lynn. / Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire. In: Cancer. 2008 ; Vol. 112, No. 10. pp. 2249-2257.
@article{66d1939d53444f83861198009d7acb90,
title = "Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire",
abstract = "BACKGROUND. The authors previously developed a melanoma-specific module for the Functional Assessment of Cancer Therapy (FACT-Melanoma), a tool for the assessment of quality of life (QOL) in patients with melanoma. The reliability and validity of the FACT-Melanoma was examined in this study. METHODS. Patients with melanoma (N = 273; stages I-IV) completed a battery of questionnaires at the time of enrollment. The validity of the instrument was examined by comparing FACT-Melanoma scores with performance status, disease stage, treatment status, and other scales, including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Melanoma Module, the Profile of Mood States, and the Marlowe-Crowne Social Desirability Scale. Patients were assessed after 1 week to assess test-retest reliability and at 3 months to determine the sensitivity of the instrument to change in performance status. RESULTS. The internal consistency and test-retest reliability (r) of the melanoma subscale (Cronbach α = .85; r = .81) and the total FACT-Melanoma (α = .95; r = .90) were excellent. Overall, the scales were correlated with other measures, as anticipated. Total FACT-Melanoma scores, along with scores for physical well-being, emotional well-being, functional well-being, and melanoma-specific scales, were lower for patients with advanced (stage III/IV) melanoma, poor performance status, and patients who were receiving active treatment. The FACT-Melanoma total score and the score for physical well-being were sensitive to changes in performance status (P = .0012 and P = .004, respectively). CONCLUSIONS. The results of the current study indicated that the FACT-Melanoma questionnaire is a reliable and valid instrument for patients with melanoma that can be used for the assessment of QOL in clinical trials.",
keywords = "Melanoma, Patient-reported outcomes, Quality of life, Test-retest reliability",
author = "Cormier, {Janice N.} and Ross, {Merrick I.} and Gershenwald, {Jeffrey E.} and Lee, {Jeffrey E.} and Mansfield, {Paul F.} and Camacho, {Luis H.} and Kevin Kim and Kimberly Webster and David Cella and Palmer, {J. Lynn}",
year = "2008",
month = "5",
day = "15",
doi = "10.1002/cncr.23424",
language = "English (US)",
volume = "112",
pages = "2249--2257",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

Cormier, JN, Ross, MI, Gershenwald, JE, Lee, JE, Mansfield, PF, Camacho, LH, Kim, K, Webster, K, Cella, D & Palmer, JL 2008, 'Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire', Cancer, vol. 112, no. 10, pp. 2249-2257. https://doi.org/10.1002/cncr.23424

Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire. / Cormier, Janice N.; Ross, Merrick I.; Gershenwald, Jeffrey E.; Lee, Jeffrey E.; Mansfield, Paul F.; Camacho, Luis H.; Kim, Kevin; Webster, Kimberly; Cella, David; Palmer, J. Lynn.

In: Cancer, Vol. 112, No. 10, 15.05.2008, p. 2249-2257.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire

AU - Cormier, Janice N.

AU - Ross, Merrick I.

AU - Gershenwald, Jeffrey E.

AU - Lee, Jeffrey E.

AU - Mansfield, Paul F.

AU - Camacho, Luis H.

AU - Kim, Kevin

AU - Webster, Kimberly

AU - Cella, David

AU - Palmer, J. Lynn

PY - 2008/5/15

Y1 - 2008/5/15

N2 - BACKGROUND. The authors previously developed a melanoma-specific module for the Functional Assessment of Cancer Therapy (FACT-Melanoma), a tool for the assessment of quality of life (QOL) in patients with melanoma. The reliability and validity of the FACT-Melanoma was examined in this study. METHODS. Patients with melanoma (N = 273; stages I-IV) completed a battery of questionnaires at the time of enrollment. The validity of the instrument was examined by comparing FACT-Melanoma scores with performance status, disease stage, treatment status, and other scales, including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Melanoma Module, the Profile of Mood States, and the Marlowe-Crowne Social Desirability Scale. Patients were assessed after 1 week to assess test-retest reliability and at 3 months to determine the sensitivity of the instrument to change in performance status. RESULTS. The internal consistency and test-retest reliability (r) of the melanoma subscale (Cronbach α = .85; r = .81) and the total FACT-Melanoma (α = .95; r = .90) were excellent. Overall, the scales were correlated with other measures, as anticipated. Total FACT-Melanoma scores, along with scores for physical well-being, emotional well-being, functional well-being, and melanoma-specific scales, were lower for patients with advanced (stage III/IV) melanoma, poor performance status, and patients who were receiving active treatment. The FACT-Melanoma total score and the score for physical well-being were sensitive to changes in performance status (P = .0012 and P = .004, respectively). CONCLUSIONS. The results of the current study indicated that the FACT-Melanoma questionnaire is a reliable and valid instrument for patients with melanoma that can be used for the assessment of QOL in clinical trials.

AB - BACKGROUND. The authors previously developed a melanoma-specific module for the Functional Assessment of Cancer Therapy (FACT-Melanoma), a tool for the assessment of quality of life (QOL) in patients with melanoma. The reliability and validity of the FACT-Melanoma was examined in this study. METHODS. Patients with melanoma (N = 273; stages I-IV) completed a battery of questionnaires at the time of enrollment. The validity of the instrument was examined by comparing FACT-Melanoma scores with performance status, disease stage, treatment status, and other scales, including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Melanoma Module, the Profile of Mood States, and the Marlowe-Crowne Social Desirability Scale. Patients were assessed after 1 week to assess test-retest reliability and at 3 months to determine the sensitivity of the instrument to change in performance status. RESULTS. The internal consistency and test-retest reliability (r) of the melanoma subscale (Cronbach α = .85; r = .81) and the total FACT-Melanoma (α = .95; r = .90) were excellent. Overall, the scales were correlated with other measures, as anticipated. Total FACT-Melanoma scores, along with scores for physical well-being, emotional well-being, functional well-being, and melanoma-specific scales, were lower for patients with advanced (stage III/IV) melanoma, poor performance status, and patients who were receiving active treatment. The FACT-Melanoma total score and the score for physical well-being were sensitive to changes in performance status (P = .0012 and P = .004, respectively). CONCLUSIONS. The results of the current study indicated that the FACT-Melanoma questionnaire is a reliable and valid instrument for patients with melanoma that can be used for the assessment of QOL in clinical trials.

KW - Melanoma

KW - Patient-reported outcomes

KW - Quality of life

KW - Test-retest reliability

UR - http://www.scopus.com/inward/record.url?scp=43049146173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049146173&partnerID=8YFLogxK

U2 - 10.1002/cncr.23424

DO - 10.1002/cncr.23424

M3 - Article

C2 - 18383513

AN - SCOPUS:43049146173

VL - 112

SP - 2249

EP - 2257

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -